ALPMF - Soild Bio sinks 13% after Sarepta data misses goal

Solid Biosciences (SLDB) down 13% premarket in sympathy with clinical data from Sarepta Therapeutics (SRPT) on Duchenne Muscular Dystrophy ((DMD)).Sarepta Therapeutics' Part 1 of Study SRP-9001-102 failed to meet primary endpoints, as a result of which shares dropped ~54% after-hours and 47% premarket.Duchenne muscular dystrophy is an inherited muscular disease. It involves muscle weakness, which quickly gets worse.Three companies — Sarepta, Pfizer (PFE) and Solid Biosciences have similar Duchenne gene therapies in human testing.Sarepta's SRP-9001, Pfizer's PF-06939926 and Solid Bio's therapy is called SGT-001. Astellas Pharma's (ALPMF) ASP-0367 is in Phase 1 development.Also, Credit Suisse analyst Martin Auster raised the recommendation on SLDB to Neutral from Underperform, with PT set to $7.See below total return performance of Solid Bio and peers over the past one year.In October 2020, Ultragenyx and Solid Bio inked deal for Duchenne gene therapies.

For further details see:

Soild Bio sinks 13% after Sarepta data misses goal